A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer By Ogkologos - November 21, 2025 246 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TRADE study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Efficacy Outcomes of Olaparib in Patients with mCRPC with BRCA Alterations... November 21, 2023 Study Links Non-Diet Soda Consumption with a Higher Risk of Death... March 16, 2021 FDA Approves Pembrolizumab Combination for the First-Line Treatment of Cervical Cancer October 15, 2021 FDA Grants Accelerated Approval to Sevabertinib for Non-Squamous NSCLC November 27, 2025 Load more HOT NEWS Perioperative Treatment with Nivolumab Results in Significantly Longer Event-Free Survival than... Finding Purpose in Sharing Your Story: A Q&A With Esophageal Cancer... What People in Asian American and Pacific Islander Communities Should Know... Marshall University Study Finds That Walnuts Suppress Breast Cancer Growth And...
